Bio protac protein having intracellular delivery function, and pharmaceutical composition comprising same

Patent metadata

Field	Value
Publication number	US-2024287206-A1
Application number	US-202218568180-A
Country	US
Kind code	A1
Filing date	Jun 10, 2022
Priority date	Jun 11, 2021
Publication date	Aug 29, 2024
Grant date	—

Abstract

The present invention relates to a proteolysis targeting chimera (PROTAC) protein having an intracellular delivery function, and a pharmaceutical composition comprising same. The PROTAC protein according to the present invention has higher solubility than a PROTAC prepared by a conventional method and efficiently degrades intrinsic disease proteins when applied to cells, and thus is effective in the treatment of cancer or inflammatory diseases.

First claim

1 . A PROTAC protein having a structure of Chemical Formula 1 or Chemical Formula 2 below:

in Chemical Formula 1 or Chemical Formula 2,
(i) PEP is an antibody or an antibody fragment, or a cell-penetrating peptide,
(ii) L 1 and L 2 are linkers, L 1 and L 2 are same as or different from each other, and L 1 binds to TB or L 2 ,
(iii) TB is a binder or conjugate that binds to a target protein,
(iv) UR is a ligand binding to a ubiquitin ligase, and
(v) n and m are each independently an integer of 1 to 10.

2 . The PROTAC protein according to claim 1 , wherein the target protein is selected from the group consisting of a mutated RAS superfamily, a kinase, a transcription factor, and a phosphatase.

3 . The PROTAC protein according to claim 2 , wherein the RAS superfamily is selected from the group consisting of KRAS, HRAS, and NRAS.

4 . The PROTAC protein according to claim 1 , wherein the TB is selected from the group consisting of a mutated RAS superfamily inhibitor, a kinase inhibitor, a phosphatase inhibitor, a heat shock protein 90 inhibitor, an MDM2 inhibitor, an HDAC inhibitor, a human lysine methyltransferase inhibitor, an angiogenesis inhibitor, an immunosuppressive compound, a compound targeting human BET bromodomain-containing protein, a compound targeting aryl hydrocarbon receptor, a compound targeting EGF (epithelial growth factor) receptor kinase, a compound targeting FKBP, a compound targeting androgen receptor, a compound targeting estrogen receptor, a compound targeting thyroid hormone receptor, a compound targeting HIV protease, a compound targeting HIV integrase, a compound targeting HCV protease, a compound targeting acyl-protein thioesterase-1, and a compound targeting acyl-protein thioesterase-2.

5 . The PROTAC protein according to claim 1 , wherein the TB is a peptide comprising any one amino acid selected from SEQ ID NO: 7 to SEQ ID NO: 14.

6 . The PROTAC protein according to claim 1 , wherein the UR is a ligand binding to an E3 ligase selected from the group consisting of XIAP, VHL protein, IAPB, cereblon, and MDM2.

7 . The PROTAC protein according to claim 1 , wherein the antibody is an antibody or a fragment thereof binding to at least one polypeptide selected from the group consisting of EGFR, DLL3, EDAR, CLL1, BMPR1B, E16, STEAP1, 0772P, MPF, NaPi2b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, B7-H4, HER2, NCA, MDP, IL20Rct, brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD22, CD79a, CXCRS, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2, TENB2, PMEL17, TMEFF1, GDNF-Ral, Ly6E, TMEM46, Ly6G6D, LGRS, RET, LY6K, GPR19, GPR54, ASPHD1, tyrosinase, TMEM118, GPR172A, MUC16, and CD33.

8 . The PROTAC protein according to claim 7 , wherein the antibody is a monoclonal antibody or a variant thereof

9 . The PROTAC protein according to claim 8 , wherein the monoclonal antibody is selected from the group consisting of trastuzumab, cetuximab, rituximab, brentuximab, gemtuzumab, inotuzumab, sacituzumab, alemtuzumab, and nimotuzumab.

10 . A nucleic acid encoding the PROTAC protein according to claim 1 .

11 . A pharmaceutical composition comprising the PROTAC protein according to claim 1 .

12 . The pharmaceutical composition according to claim 11 , in which used to treat or prevent cancer or an inflammatory disease.

13 . The pharmaceutical composition according to claim 12 , in which used to treat or prevent a disease selected from the group consisting of cancer, asthma, autoimmune disease, rheumatoid arthritis, multiple sclerosis, ciliary disease, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Engelman syndrome, Canavan disease, chronic digestive disorder, Charcot-Marie-Tooth disease, cystic fibrosis, Duchenne muscular dystrophy, hemochromatosis, hemophilia, Klinefelter syndrome, neurofibromatosis, phenylketonuria, autosomal dominant polycystic neoplasm (PKD1 or PKD2), Prader-Willi syndrome, sickle cell anemia, Tay-Sachs disease, Turner syndrome, HIV-infected disease, and HCV-infected disease.

14 . The pharmaceutical composition according to claim 12 , wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, bowel cancer, breast cancer, cervical cancer, uterine cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, gastric cancer, leukemia, benign and malignant lymphoma, benign and malignant melanoma, myeloproliferative disease, sarcoma including Ewing sarcoma, angiosarcoma, Kaposi sarcoma, liposarcoma, myoma, neuroepithelial sarcoma, synovial sarcoma, neurosarcoma, astrocytoma, oligodendrogliocytoma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineocytoma, meningioma, meningeal sarcoma, neurofibroma, and schwannoma, testicular cancer, thyroid cancer, carcinosarcoma, Hodgkin disease, Wilms tumor, and teratocalcinomas.

15 . The pharmaceutical composition according to claim 12 , wherein the inflammatory disease is selected from the group consisting of arthritis, autoimmune disease, Parkinson's disease, dementia, hepatitis, and viral infection.

16 . The pharmaceutical composition according to claim 12 , in which administered via oral, parenteral, inhalation spray, topical, rectal, nasal, or implanted reservoir routes.

17 . The pharmaceutical composition according to claim 16 , in which administered using nanoparticles or liposomes as a carrier upon oral or parenteral administration.

Assignees

• Nibec Co Ltd
• Seoul Nat Univ R&Db Foundation

Inventors

• Park Yoon Jeong
• Chung Chong-Pyoung
• Lee Jue-Yeon
• Yoon Gook-Jin

Classifications

• C07K14/47

  from mammals · CPC title

• C07K2319/95

  containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence) · CPC title

• C07K2319/01

  containing a localisation/targetting motif · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title